Tempest Therapeutics, Inc. (NASDAQ:TPST) Sees Significant Increase in Short Interest

Tempest Therapeutics, Inc. (NASDAQ:TPST) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 969,700 shares, a growth of 26.5% from the March 15th total of 766,800 shares. Based on an average daily trading volume, of 1,030,000 shares, the short-interest ratio is presently 0.9 days. Currently, 6.1% of the shares of the company are short sold.

Analyst Ratings Changes

A number of brokerages have recently issued reports on TPST. William Blair reissued an “outperform” rating on shares of Tempest Therapeutics in a research report on Wednesday, March 20th. Jefferies Financial Group initiated coverage on shares of Tempest Therapeutics in a research report on Thursday, February 8th. They set a “buy” rating and a $15.00 target price on the stock. Scotiabank started coverage on shares of Tempest Therapeutics in a research report on Thursday, March 14th. They issued a “sector outperform” rating and a $13.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and set a $47.00 price objective on shares of Tempest Therapeutics in a research note on Wednesday, March 20th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TPST. Worth Venture Partners LLC bought a new position in shares of Tempest Therapeutics in the second quarter worth about $129,000. Renaissance Technologies LLC increased its position in Tempest Therapeutics by 290.2% during the 2nd quarter. Renaissance Technologies LLC now owns 103,401 shares of the company’s stock worth $131,000 after purchasing an additional 76,901 shares in the last quarter. Geode Capital Management LLC lifted its stake in Tempest Therapeutics by 52.9% in the 2nd quarter. Geode Capital Management LLC now owns 102,244 shares of the company’s stock valued at $130,000 after purchasing an additional 35,372 shares during the last quarter. Northern Trust Corp boosted its position in Tempest Therapeutics by 147.9% in the fourth quarter. Northern Trust Corp now owns 33,598 shares of the company’s stock valued at $148,000 after buying an additional 20,045 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in shares of Tempest Therapeutics during the second quarter worth $29,000. Institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Stock Performance

Shares of Tempest Therapeutics stock opened at $3.59 on Monday. The company has a 50 day moving average of $3.86 and a 200-day moving average of $3.74. The company has a market cap of $79.66 million, a PE ratio of -1.88 and a beta of -1.76. The company has a current ratio of 4.29, a quick ratio of 4.29 and a debt-to-equity ratio of 0.23. Tempest Therapeutics has a 1-year low of $0.17 and a 1-year high of $9.77.

Tempest Therapeutics (NASDAQ:TPST) last released its earnings results on Tuesday, March 19th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.04. As a group, equities research analysts forecast that Tempest Therapeutics will post -1.58 earnings per share for the current fiscal year.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.